NovoCure Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-136.23	-168.63	-207.04	-92.53
Depreciation & Amortization	14.65	11.24	10.97	10.62
Stock-Based Compensation	104.83	160.04	115.61	106.96
Other Adjustments	-1.36	-17.97	-18.45	1.05
Change in Receivables	-38.94	-26.36	29.41	2.55
Changes in Inventories	-5.67	2.57	-8.92	-4.34
Changes in Accounts Payable	18.96	19.11	14.87	14.26
Changes in Other Operating Activities	-5.27	-6.36	-9.78	-7.77
Operating Cash Flow	-49.03	-26.37	-73.34	30.79
Capital Expenditures	-26.65	-42.86	-27.09	-21.36
Purchases of Investments	-821.08	-875.39	-1,004	-1,298
Proceeds from Sale of Investments	1,285	778	1,215	1,179
Investing Cash Flow	437.28	-140.24	184.15	-139.96
Long-Term Debt Issued	99.98	96.92	-	-
Long-Term Debt Repaid	-560.95	-12.91	-0.01	-0.03
Net Long-Term Debt Issued (Repaid)	-460.97	84.01	-0.01	-0.03
Issuance of Common Stock	9.77	6.31	15.8	15.52
Net Common Stock Issued (Repurchased)	9.77	6.31	15.8	15.52
Other Financing Activities	-0.15	-	-	-
Financing Cash Flow	-451.34	90.32	15.79	15.49
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.39	-0.17	0.13	-0.1
Net Cash Flow	-62.7	-76.47	126.73	-93.78
Free Cash Flow	-75.68	-69.22	-100.43	9.43
FCF Margin	-11.55%	-11.44%	-19.72%	1.75%
Free Cash Flow Per Share	-0.68	-0.64	-0.94	0.09
Levered Free Cash Flow	-601.18	-100.92	-227.01	-101.15
Unlevered Free Cash Flow	-157.76	-235.5	-271.41	-109.81

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q